Short answer
GLAUKOS Corp (GKOS) filed its Q3 2025 10-Q quarterly report on Oct 31, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $134M (up 38.1% year over year) with net income of −$16M.
Q3 2025 key financials · XBRL
- Revenue
- $134M
- +38.1% YoY · +7.6% QoQ
- Net income
- −$16M
- +24.2% YoY · +17.4% QoQ
- Operating margin
- -12.3%
- Gross margin
- 78.4%
- EPS (diluted)
- −$0.29
- +19.4% YoY · +14.7% QoQ
Source: XBRL data from the GLAUKOS Corp (GKOS) Q3 2025 10-Q on SEC EDGAR. USD.
GLAUKOS Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: MIGS restrictions by five MACs limiting iStent sales volume, impacting U.S. glaucoma product revenue growth
- Updated operational risk: $80M+ planned capital expenditure for new Huntsville, AL R&D and manufacturing facility starting 2026
- Regulatory risk: Government rebate obligations and MDRP participation affecting net sales and accrued rebates on Photrexa products
- Market risk: 57% increase in U.S. glaucoma sales driven by higher iDose TR volume offset by iStent sales decline due to LCD restrictions
- Financial risk: Cash, cash equivalents, and short-term investments total $273.7M, with $367.3M net working capital sufficient for short-term liabilities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GLAUKOS Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.